Vanguard Group Inc. increased its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 15.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,374,970 shares of the biotechnology company’s stock after buying an additional 1,003,594 shares during the quarter. Vanguard Group Inc. owned 4.06% of Cerevel Therapeutics worth $312,699,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Cerevel Therapeutics in the fourth quarter worth $71,000. Centaurus Financial Inc. purchased a new position in Cerevel Therapeutics during the 4th quarter valued at $119,000. PNC Financial Services Group Inc. increased its position in Cerevel Therapeutics by 68.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 9,506 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 3,866 shares during the period. GAM Holding AG bought a new stake in Cerevel Therapeutics during the 4th quarter valued at approximately $212,000. Finally, Virtu Financial LLC purchased a new position in shares of Cerevel Therapeutics during the 4th quarter worth approximately $246,000. 87.73% of the stock is owned by hedge funds and other institutional investors.
Cerevel Therapeutics Stock Up 1.0 %
CERE stock opened at $40.89 on Friday. Cerevel Therapeutics Holdings, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $43.59. The business’s 50 day moving average price is $41.52 and its two-hundred day moving average price is $41.83. The company has a debt-to-equity ratio of 0.60, a quick ratio of 10.22 and a current ratio of 10.22. The company has a market capitalization of $7.45 billion, a price-to-earnings ratio of -14.98 and a beta of 1.41.
Insiders Place Their Bets
In other Cerevel Therapeutics news, Director N Anthony Coles sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00. Following the transaction, the director now owns 15,638 shares in the company, valued at approximately $658,359.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.
Cerevel Therapeutics Profile
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Read More
- Five stocks we like better than Cerevel Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 6/24 – 6/28
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Want to see what other hedge funds are holding CERE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report).
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.